Iran will start receiving doses of the AstraZeneca vaccine in February via the Covid-19 Vaccines Global Access (COVAX) platform, Minister of Health and Medical Education Saeed Namaki announced.
"AstraZeneca informed us the night before last that it will start delivering 4.2 million doses in February within the framework of COVAX," Namaki said in a video announcement on Wednesday.
Namaki also said that Iran's Razi Vaccine and Serum Research Institute has been authorised to start clinical trials of its vaccine candidate, and they will hopefully start the trials next week.
At her daily briefing, spokeswoman for the ministry, Sima Sadat Lari, said 6,870 new Covid-19 cases were detected in the past 24 hours, raising the country's overall count to 1,438,286 infections.
Of the newly infected, she noted, 701 had to be hospitalised.
Between Tuesday and Wednesday, she added, 79 new deaths related to the coronavirus were registered, taking a death toll of 58,189 in the country.
She said 1,229,391 Covid-19 patients have as of Wednesday recovered or been released from Iranian hospitals.
So far, 9,449,685 tests for Covid-19 have been carried out in Iran, according to the spokesperson.
Iran announced its first Covid-19 cases on February 19, 2020.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.